Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Cytosorbents (CTSO) over the last 14 years, with Q3 2025 value amounting to $12.8 million.

  • Cytosorbents' Gains from Investment Securities rose 192.31% to $12.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.8 million, marking a year-over-year increase of 192.31%. This contributed to the annual value of $12.3 million for FY2024, which is 1700.52% up from last year.
  • According to the latest figures from Q3 2025, Cytosorbents' Gains from Investment Securities is $12.8 million, which was up 192.31% from $12.2 million recorded in Q2 2025.
  • Over the past 5 years, Cytosorbents' Gains from Investment Securities peaked at $12.8 million during Q3 2025, and registered a low of -$174802.0 during Q4 2022.
  • For the 5-year period, Cytosorbents' Gains from Investment Securities averaged around $8.8 million, with its median value being $8.8 million (2023).
  • As far as peak fluctuations go, Cytosorbents' Gains from Investment Securities crashed by 10253.85% in 2022, and later skyrocketed by 613435.54% in 2023.
  • Over the past 5 years, Cytosorbents' Gains from Investment Securities (Quarter) stood at $6.9 million in 2021, then plummeted by 102.54% to -$174802.0 in 2022, then surged by 6134.36% to $10.5 million in 2023, then rose by 17.01% to $12.3 million in 2024, then increased by 3.31% to $12.8 million in 2025.
  • Its Gains from Investment Securities was $12.8 million in Q3 2025, compared to $12.2 million in Q2 2025 and $12.3 million in Q1 2025.